--- title: Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business description: Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business image: https://blog.congenica.com/hubfs/David%20Atkins.jpg --- - [Our Customers and Partners](http://www.congenica.com/our-customers) - [Our Product Portfolio](http://www.congenica.com/congenica-products) - **Inherited Diseases** - [Rare Disease](http://www.congenica.com/congenica-rare-disease) - [Inherited Cancer](http://www.congenica.com/congenica-inherited-cancer) - [Prenatal Health](http://www.congenica.com/congenica-prenatal) - [Carrier Screening](http://www.congenica.com/congenica-carrier-screening) - [Neurodevelopmental Disorders](http://www.congenica.com/congenica-neuro) - **Somatic Oncology** - [Solid Tumours](http://www.congenica.com/congenica-oncology) - **Pathogen** - [Pathogen Surveillance](http://www.congenica.com/congenica-pathogen-surveillance) - [Our Services](http://www.congenica.com/congenica-services) - [Clinical Interpretation Services](http://www.congenica.com/congenica-clinical-interpretation-services) - [Professional Services](http://www.congenica.com/professional-services) - [Customer Support](http://www.congenica.com/customer-support) - [Pharma Services](http://www.congenica.com/pharma-services) - Resources - [Publications](http://www.congenica.com/publications) - [Supporting materials](http://www.congenica.com/resources) - [News](https://blog.congenica.com/) - [Events and webinars](http://www.congenica.com/events-webinars) - [About us](http://www.congenica.com) - [Leadership Team](http://www.congenica.com/leadership) - [Quality](http://www.congenica.com/quality) - [Investors](http://www.congenica.com/investors) - [People and Vacancies](http://www.congenica.com/people) - [Contact us](http://www.congenica.com/contact) Login ##### Please select your location and reference genome: [America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/) [Overview](https://blog.congenica.com) [Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business](https://blog.congenica.com/2018/01/25/congenica-appoints-new-ceo) ![Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business](https://blog.congenica.com/hubfs/David%20Atkins.jpg) News # Congenica Appoints New CEO to Drive Global Expansion of Clinical Genomics Business 1/25/2018    |    0 min read ![](https://blog.congenica.com/hs-fs/hubfs/Imported_Blog_Media/David-Atkins-Website.png?width=288&height=360&name=David-Atkins-Website.png) **Cambridge, United Kingdom – 25 January 2018 –** Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK, Dr Atkins also joins Congenica’s Board of Directors. Dr Atkins has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Prior to joining Congenica, Dr Atkins was previously CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. Past roles also include global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. Dr Atkins also has over 20 years’ experience with Johnson & Johnson’s Medical Device and Diagnostic businesses in R&D and business development and most recently senior international commercial roles. Dr Atkins holds a B.Sc. and Ph.D. from the University of East Anglia, UK, a Graduate Certificate in Pharmacology from the University of New South Wales, Australia and an MBA from Columbia University, USA. Welcoming Dr Atkins to the Company, Dr Andy Richards, Chairman of Congenica, said: “David has an impressive international track record of success in leading and scaling healthcare technology companies. I am delighted that he has chosen to join Congenica at this pivotal time in the Company’s development. He will lead Congenica’s international growth as it rolls out its commercial operations across Europe and into the USA and Asia, and oversee further product development of Sapientia™, its gold-standard clinical genomics analysis platform. I look forward to working with David and the Board of Congenica to fulfil its potential in this exciting market.” Dr Atkins succeeds co-founder and CEO Dr. Tom Weaver, who will continue to serve on the Board, as well as interim-CEO Dr. Nick Lench, who will continue in his COO role. Dr Weaver said: “I am really excited that David will lead the next phase of our business. There is no better time for someone with his talent and experience to join our executive team and drive our rapid growth.” Dr Richards added “I have been really pleased with the way that David has integrated with the founders and the exec team at Congenica and I would particularly like to thank both Tom Weaver and Nick Lench for their contribution and the support that they have given the company; I look forward to continuing to work with both of them as valued members of the team and Board at Congenica” Dr David Atkins, Congenica’s new CEO, said: “It has always been a privilege to be involved in businesses that focus on providing solutions to patients. I am looking forward to working with the impressive team at Congenica to drive the company’s expansion at a time when genomics is set to truly revolutionise medicine and patient care. Our world-leading Sapientia™ platform quickly, accurately and cost-effectively diagnoses rare genetic diseases, supporting clinicians in their decision making and, ultimately, changing patient lives.” 2017 was a successful year for Congenica, positioning it for growth in 2018. It completed a successful [Series B financing round](https://blog.congenica.com/2017/04/27/congenica-completes-series-b-financing-round-investments-china-based-bgi-healthlink-future-planet), raising $13.5M from leading China- and UK-based investors. It also expanded its operations in China and the US, formally incorporating a US operation in April 2017. In addition to the use of Congenica’s Sapientia™ clinical genomics platform in Genomics England’s ground-breaking [100K Genomes Project](https://blog.congenica.com/2016/08/26/100000-genomes-project-congenica-first-uk-company-deliver-diagnostic-reports), the Company also secured collaborations to support China’s national [100K Wellness project](https://blog.congenica.com/2017/06/21/beijing-4p-health-research-institute) and Portugal’s [In2Genome Project.](https://blog.congenica.com/2017/09/06/sapientia-in2genome-genetic-project) --- ### Related articles ![SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/hs-fs/hubfs/New%20logos/Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png?width=320&height=192&name=Congenica%20%26%20SeqOne%20Logo%20Without%20Tagline%20RGB.png) 9/2/2025 #### [SeqOne acquires Congenica to create a global leader in AI-powered genomic medicine](https://blog.congenica.com/seqone-acquires-congenica-to-create-a-global-leader-in-ai-powered-genomic-medicine) Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries ![Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/hs-fs/hubfs/male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg?width=320&height=192&name=male%20doc%20with%20child%20and%20mum%20light%20small%20.jpg) 11/6/2024 #### [Congenica showcased in Genomics Spotlight 2024 Report](https://blog.congenica.com/congenica-showcased-in-recently-launched-genomics-spotlight-2024-report) We are thrilled to announce that Congenica is one of the companies showcased in the recently launched Genomics Spotlight 2024 report produced by the UK Department for Business and Trade (DBT). ![Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/hs-fs/hubfs/Onco%20.png?width=320&height=192&name=Onco%20.png) 6/19/2024 #### [Congenica Named Best Genomic Data Analysis Software Company 2024 by GHP](https://blog.congenica.com/congenica-named-best-genomic-data-analysis-software-company-2024-by-ghp) We are thrilled to announce that Congenica has been awarded the title of "Best Genomic Data Analysis Software Company 2024" by Global Health & Pharma Magazine.  ##### Congenica is available as a CE Marked IVD clinical decision support platform for clinical diagnostic use for inherited genetic disorders in the UK and EU, Iceland, Lichtenstein, Norway, Switzerland and Turkey. In all other countries, ensuring compliance with relevant local, national and international clinical laboratory regulations is the responsibility of the laboratory. - [Privacy Policy](http://www.congenica.com/privacy-policy) - [Cookie Policy](http://www.congenica.com/cookie-policy) Log in to Congenica ##### Please select your location and reference genome: [America - GRCh37](https://us-37.congenica.com/) [America - GRCh38](https://us-38.congenica.com/) [Europe, Middle East, Africa - GRCh37](https://eu-37.congenica.com/) [Europe, Middle East, Africa - GRCh38](https://eu-38.congenica.com/) ![CE](https://blog.congenica.com/hs-fs/hubfs/CE.png?width=80&height=80&name=CE.png) ![ISO-27001](https://blog.congenica.com/hs-fs/hubfs/ISO-27001.jpg?width=80&height=80&name=ISO-27001.jpg) ![TR-Testmark_9000030872_EN_2024_CMYK](https://blog.congenica.com/hs-fs/hubfs/2023%20website%20images/TR-Testmark_9000030872_EN_2024_CMYK.png?width=80&height=80&name=TR-Testmark_9000030872_EN_2024_CMYK.png) ![HIPAA Compliant](https://blog.congenica.com/hs-fs/hubfs/HIPAA%20Compliant.png?width=80&height=80&name=HIPAA%20Compliant.png) Copyright © 2026 Congenica Ltd. Company number: 8273616 Registered in England and Wales.